Conventional Oncology’s Limitations
While conventional oncology has been more successful with the “liquid” cancers (e.g. lymphomas and leukemia), it has over-all failed with regard to the safe and efficient control and reversal of “solid” cancers, which constitute the vast majority of malignancies that affect humans.
“The overall contribution of curative and adjuvant cytotoxic chemotherapy to 5-year survival in adults was estimated to be 2.3% in Australia and 2.1% in the USA”. Cf. Morgan G1, Ward R, Barton, The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. M. Clin Oncol (R Coll Radiol). 2004 Dec;16(8):549-60. (Source) (1)
Resistance to chemotherapy and molecularly targeted therapies with high recurrence rates have been a major hallmark of conventional oncology. (2) Not only can chemotherapy worsen the tumor’s micro-environment, it can also make the cancer circulating stem cells, which are the engins of metastases, mutate and spread even more. Radiation has similar effects. (Source) Likewise with many biopsies and surgeries, they too can significantly contribute to the spreading of malignancies, via the cellular adhesion, immune suppression, surgical stress and inflammatory pathways. And to make matters worse, many conventional diagnoses and prognoses have built-in and often fatal flaws.
On the other hand, with well-designed holistic and metabolic cancer protocols, most cancer patients can expect a 50 to 100 percent survivability success rate, defined as at least five years of remission, with few if any side effects. (3)
(1). This Study is the result of close to one hundred studies incorporated within this meta-analysis. Other meta-analyses confirm this one, where less than 3 percent of cancer patents make it to five 5 years. This is true only when chemo is used as a stand alone. When more holistic techniques accompany chemo, radiation or surgery, the results are a little better. For the liquid cancers, the 5 years rate of survival can reach 40 to 50 percent. But what is usually not stated is that many of these cancers tend to come back after the 5 years mark. And if they do, they are considered to be new cancers.
(2). The mechanisms of resistance to conventional cytotoxic chemotherapeutics share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death. (Source). In the end, most advanced cancer patients tend not to survive relapse.
(3). Unless the patient first adopted a harmful conventional treatment and-or is not compliant to the holistic protocol. Given the costs (hundreds of millions to billions of dollars), human RCT (randomized control trials) can’t exist in holistic oncology, if only because most of holistic oncology is lifestyle medicine and this type of medicine is not patentable, nor can it be squeezed into a double blind RCT. On the other hand, there are a few prospective and observational studies that confirm holistic and integrative oncology’s clinical superiority over conventional oncololgy, See blog.
Copyright (c) 2015: Advanced Cancer Research Institute, Pr Joubert and agents. All rights reserved. In terms of “fair use”, the Institute allows the free use of this posted article provided it is not altered, full attribution is included as well as the Institute’s Post URL link. Furthermore, consistent with “fair use” case law, small sections from the Institute’s posted article can be used as long as the above mentioned attributions are made and as long as the usage purpose is based on furthering education and science. For any other usage reason, written permission is required.